SRX sierra rutile holdings limited

TARE with Yttrium-90 for the Treatment of HCC

  1. 8,918 Posts.
    lightbulb Created with Sketch. 32
    http://link.springer.com/article/10.1007/s12325-016-0324-7/fulltext.html

    Full text available above.
    My bold below
    ----------------------------------------------------
    Results

    TARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy.
    Conclusion

    TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.